At the 2022 ASCO Annual Meeting, Dr. Ann Partridge, of Dana-Farber Cancer Institute, discussed trends in breast cancer with several colleagues. On this episode, we’re featuring two of those conversations: one on antibody-drug conjugates, and another on endocrine therapy plus ribociclib for progressive breast cancer.

To listen to more podcasts from ASCO, visit asco.org/podcasts.